Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Shepherd

Showing results (1091-1100 of 1,281) with videos related to

Pageof 129
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2015
Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete ResectionMing-Sound Tsao, Sophie Marguet, Gwénaël Le Teuff, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2018
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLCScott Gettinger, Matthew D Hellmann, Laura Q M Chow, et al.
Pharmacogenetics and Genomics|July 22, 2009
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomesPenelope A Bradbury, Matthew H Kulke, Rebecca S Heist, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)Catherine Labbé, Michael Cabanero, Grzegorz J Korpanty, et al.
Lung Cancer (Amsterdam, Netherlands)|February 20, 2022
Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancerSabine Schmid, Miguel Garcia, Sierra Cheng, et al.
Current Oncology (Toronto, Ont.)|December 31, 2020
Longitudinal health utilities, symptoms and toxicities in patients with <i>ALK-</i>rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessmentB C Tse, B I Said, Z J Fan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2015
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung CancerGiorgio Scagliotti, Joachim von Pawel, Silvia Novello, et al.
The Journal of Molecular Diagnostics : JMD|May 12, 2015
Analytical Performance of a 15-Gene Prognostic Assay for Early-Stage Non-Small-Cell Lung Carcinoma Using RNA-Stabilized TissueShuguang Huang, Nicholas J Reitze, Amy L Ewing, et al.
Breast Cancer Research : BCR|October 30, 2019
Automated volumetric breast density measures: differential change between breasts in women with and without breast cancerKathleen R Brandt, Christopher G Scott, Diana L Miglioretti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Second-hand smoke as a predictor of smoking cessation among lung cancer survivorsLawson Eng, Jie Su, Xin Qiu, et al.
Pageof 129

Showing results (1091-1100 of 1,281) with videos related to

Sort By:
Pageof 129
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2015
Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete ResectionMing-Sound Tsao, Sophie Marguet, Gwénaël Le Teuff, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2018
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLCScott Gettinger, Matthew D Hellmann, Laura Q M Chow, et al.
Pharmacogenetics and Genomics|July 22, 2009
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomesPenelope A Bradbury, Matthew H Kulke, Rebecca S Heist, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)Catherine Labbé, Michael Cabanero, Grzegorz J Korpanty, et al.
Lung Cancer (Amsterdam, Netherlands)|February 20, 2022
Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancerSabine Schmid, Miguel Garcia, Sierra Cheng, et al.
Current Oncology (Toronto, Ont.)|December 31, 2020
Longitudinal health utilities, symptoms and toxicities in patients with <i>ALK-</i>rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessmentB C Tse, B I Said, Z J Fan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2015
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung CancerGiorgio Scagliotti, Joachim von Pawel, Silvia Novello, et al.
The Journal of Molecular Diagnostics : JMD|May 12, 2015
Analytical Performance of a 15-Gene Prognostic Assay for Early-Stage Non-Small-Cell Lung Carcinoma Using RNA-Stabilized TissueShuguang Huang, Nicholas J Reitze, Amy L Ewing, et al.
Breast Cancer Research : BCR|October 30, 2019
Automated volumetric breast density measures: differential change between breasts in women with and without breast cancerKathleen R Brandt, Christopher G Scott, Diana L Miglioretti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Second-hand smoke as a predictor of smoking cessation among lung cancer survivorsLawson Eng, Jie Su, Xin Qiu, et al.
Pageof 129